SARS-CoV-2 mutations (VOC-202012/01, 501.V2) and vaccination

Press Release  -  December 31st 2020

SARS-CoV-2 mutations (VOC-202012/01, 501.V2) and vaccination

MEDsan UK’s coronavirus tests are made in Hamburg by the sanaGroup. Here is a statement from the sanaGroup regarding the new mutations of the virus.

The sanaGroup informs that according to current knowledge the latest mutations (VOC-202012/01, 501.V2) have no effect on the results of in vitro diagnostics of the sanaGroup for the detection of SARS-CoV-2 or COVID-19.

The current mutations in SARS-CoV-2 from Great Britain, South Africa and Nigeria, which are currently detected in many other countries, are mainly related to the spike protein (S protein) and not to the nucleocapsid protein (N protein).

MEDsan® SARS-CoV-2 Antigen Rapid Test / MEDsan® Multiplex (SC2 & Flu A/B) Rapid Test & MEDsan® COVID-19 IgM/IgG Rapid Test Hybrid / MEDsan® COVID-19 IgM/IgG Rapid Test

The sanaGroup product MEDsan® COVID-19 IgM/IgG Rapid Test Hybrid detects antibodies that bind specifically to the N protein and is therefore not significantly influenced by the currently circulating mutations or the use of the vaccines.

The products MEDsan® SARS-CoV-2 Antigen Rapid Test and MEDsan® Multiplex (SC2 & Flu A/B) Rapid Test use only antibodies that form a specific bond with the N protein. In addition, sanaGroup confirms that vaccination with the currently approved vaccines does not affect the test results when using these products.

As sanaGroup further informs, the product MEDsan® COVID-19 IgM/IgG Rapid Test can demonstrate antibody formation in response to the disease COVID-19 as well as to a vaccination against SARS-CoV-2.

About sanaGroup

sanaGroup is a family-owned biotech and pharmaceutical company with the focus on the development, manufacture and marketing of pharmaceutical and diagnostic products. The headquarters are located in Hamburg. With more than 44 years of experience and with our 680 employees worldwide, sanaGroup has a wide range of immunobiological pharmaceuticals, medical devices and diagnostic solutions worldwide. The companies MEDsan® and BioeXsen GmbH are focused on the development and production of in vitro diagnostics especially in the field of rapid tests and Ultra PCR solutions. The developments are based on the latest research findings and innovative technologies.